Noradrenergic, Serotonergic and Dopaminergic Modulation in AD‐Brexpiprazole

This talk will discuss brexpiprazole as well as comparisons to similar treatments that act as modulators to the NSS system. It will discuss the advantages, side effects, potential risks and implications for further research to reduce symptom burden and potentiate disease modification.

Authors

Elizabeth Crocco (ORCID: https://orcid.org/0000-0002-0917-386X)

Institutions

University of Miami (US)

Publication Details

Journal: Alzheimer s & Dementia
Published: 2025-12-01
DOI: https://doi.org/10.1002/alz70857_098884
Primary Topic: Attention Deficit Hyperactivity Disorder
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Noradrenergic, Serotonergic and Dopaminergic Modulation in AD‐Brexpiprazole

Elizabeth Crocco

Dec 1, 2025

Alzheimer s & Dementia

Attention Deficit Hyperactivity Disorder

article

Noradrenergic, Serotonergic and Dopaminergic Modulation in AD‐Brexpiprazole

Elizabeth Crocco

December 1, 2025article en

Abstract

Alzheimer s & DementiaVol. 21(S3)

University of Miami (US)

Good health and well-being

Openalex Percentile: Top 34%

Attention Deficit Hyperactivity Disorder

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Noradrenergic, Serotonergic and Dopaminergic Modulation in AD‐Brexpiprazole — Elizabeth Crocco · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS